Fullhope Biomedical Co

Fullhope Biomedical Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Fullhope Biomedical Co (7773.TWO) as of Oct 16, 2026 is -10.58. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -19.53 — a change of -45.85% (higher).

EV/FCF

-10.58

YoY

-45.85%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Fullhope Biomedical Co is 2024 -10.58 . EV/FCF (Enterprise Value to Free Cash Flow) of Fullhope Biomedical Co was 2023 -19.53 . It decreases by -45.85% higher compared to the previous year.

The Fullhope Biomedical Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2022
-28.94 TWD
Jan 1, 2023
-19.53 TWD
Jan 1, 2024
-10.58 TWD
The Fullhope Biomedical Co EV/FCF history
YEAREV/FCFYoY
-10.58-45.85%
-19.53-32.52%
-28.94—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fullhope Biomedical Co Stock analysis

What does Fullhope Biomedical Co do? Fullhope Biomedical Co Ltd is a Taiwan-based biotechnology company headquartered in Taipei. The company operates in the health care sector with a focus on precision diagnosis and regenerative medicine. Fullhope Biomedical went public on September 26, 2024, with its ticker listed as 7773.TWO. The company's website is https://www.fhb.com.tw/. In the precision diagnosis sector, Fullhope Biomedical has developed an immune function analysis platform and a circulating tumor cell analysis platform. These platforms provide comprehensive information on immune system status and circulating tumor cell data, which can inform follow-up disease treatment strategies. For regenerative medicine, the company maintains a Good Tissue Practice (GTP) laboratory that adheres to regulatory standards. It has established a full-scale manufacturing platform for immune cells and stem cells, producing various cell-based products. The company's operations are based in Taipei, Taiwan, and it is engaged in developing and commercializing products related to precision diagnostics and regenerative medicine. Fullhope Biomedical's business model centers on leveraging advanced biotechnological platforms to support medical treatments and patient care. The company's IPO date marks its entry into the public market, reflecting its growth and development in the biotechnology industry. Fullhope Biomedical's focus on innovative diagnostic and therapeutic solutions positions it within the expanding health care technology sector. Fullhope Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fullhope Biomedical Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of Fullhope Biomedical Co is -10.58 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of Fullhope Biomedical Co changed from -19.53 to -10.58, representing a -45.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Fullhope Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Fullhope Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Fullhope Biomedical Co

All Key Metrics — Fullhope Biomedical Co